ProstaScint prostate cancer imaging agent: Marketed

CYTO said ProstaScint identified metastatic sites beyond the prostate in 62 percent of post-prostatectomy patients with elevated prostate specific antigen (PSA), allowing use of salvage radiation therapy tailored to the sites. ...